Status:
RECRUITING
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
Lead Sponsor:
Telios Pharma, Inc.
Conditions:
Allergic Conjunctivitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 60 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic e...
Eligibility Criteria
Inclusion
- Individuals aged 18 years or older
- Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study.
- Documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at Visit 1 or within the past 60 months.
- Calculated best-corrected visual activity
- Positive bilateral CAC reaction
Exclusion
- Any systemic or ocular disease currently producing ocular redness and/or ocular discomfort, or that may interfere with the conduct of the study.
- Any ocular surgical intervention within the last 3 months OR refractive surgery within the last 6 months
- Any ongoing ocular infection (bacterial, viral or fungal)
Key Trial Info
Start Date :
October 23 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT07220408
Start Date
October 23 2025
End Date
February 1 2026
Last Update
November 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Advancing Vision Research
Smyrna, Tennessee, United States, 37167